

CQ6-11 心原性ショックを伴う成人敗血症患者に対して強心薬を使用するか？

検索データベース

- MEDLINE (PubMed/Ovid)
- CENTRAL
- 医学中央雑誌
- その他 ()

検索式とヒット数

PubMed search strategy (検索日 2019 年 5 月 11 日)

#1	("systemic inflammatory response syndrome"[MeSH Terms] OR Systemic Inflammatory Response Syndrome[Tiab] OR (Sepsis[MeSH] OR "Shock, Septic"[MesH] OR sepsis[tiab] OR (Septic[tiab] AND shock[tiab]))	179759
#2	"shock"[MeSH Terms] OR shock[tiab] OR "cardiomyopathies"[MeSH Terms] OR cardiomyopathy[tiab] OR "early goal-directed therapy"[MeSH Terms] OR early goal directed therapy[tiab] OR "critical illness"[MeSH Terms] OR critically ill[tiab] OR "resuscitation"[MeSH Terms] OR resuscitation[tiab] OR "multiple organ failure"[Mesh] OR "organ failure"[tiab] OR "organ dysfunction"[tiab] OR "MOF"[tiab] OR "MODS"[tiab]	476599
#3	"bacteremia"[MeSH Terms] OR Bacteremia[tiab]	40609
#4	"dobutamine"[MeSH Terms] OR Dobutamine[tiab] OR "epinephrine"[MeSH Terms] OR adrenaline[tiab] OR "phosphodiesterase inhibitors"[tiab] OR "phosphodiesterase inhibitors"[MeSH Terms] OR Inotropic[tiab] AND agent[tiab] OR "aminopyridines"[MeSH Terms] OR Aminopyridines[tiab] OR "simendan"[MeSH Terms] OR levosimendan[tiab]	18195
#5	randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR "clinical trials as topic"[MeSH Terms:noexp] OR randomly[tiab] OR trial[ti] NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])	1125461
#6	#1 OR #2 OR #3	608407
#7	#6 AND #4 AND #5	189

CENTRAL search strategy(検索日 2019 年 5 月 11 日)


#1	MeSH descriptor: [Systemic Inflammatory Response Syndrome]	4357
#2	(systemic inflammatory response syndrome):ti.ab.kw	1204
#3	Mesh descriptor:[Sepsis] explode all trees	11320
#4	(sepsis):ti.ab.kw	10323
#5	Mesh descriptor:[Septic shock] explode all trees	2947
#6	(septic shock):ti.ab.kw	2773
#7	dobutamine	1340
#8	(dobutamine):ti,ab,kw	1306
#9	epinephrine	7401
#10	(epinephrine):ti,ab,kw	7241
#11	phosphodiesterase inhibitors	1735
#12	(phosphodiesterase inhibitors):ti,ab,kw	1646
#13	aminopyridines	191
#14	(aminopyridines):ti,ab,kw	188
#15	simendan	225
#16	simendan	225
#17	levosimendan	433
#18	(levosimendan):ti,ab,kw	431
#19	#1 OR #2 OR #3 OR #4 OR #5 OR #6	14922
#20	#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18	10736
#21	#19 AND #20	312

医学中央雑誌 search strategy(2019 年 5 月 11 日)

#1	(systemic/AL and inflammatory/AL and response/AL and (症候群/TH or syndrome/AL)) and (PT=会議録除く)	17551
#2	((敗血症/TH or sepsis/AL)) and (PT=会議録除く)	15,911
#3	(Shock,/AL and Septic/AL) and (PT=会議録除く)	24
#4	((Dobutamine/TH or dobutamine/AL)) and (PT=会議録除く)	1477
#5	((Epinephrine/TH or epinephrine/AL)) and (PT=会議録除く)	9048

#6	((("Phosphoric Diester Hydrolases"/TH or phosphodiesterase/AL) and inhibitors/AL) and (PT=会議録除<))	1200
#7	((Aminopyridines/TH or aminopyridines/AL)) and (PT=会議録除<))	1201
#8	((Simendan/TH or simendan/AL)) and (PT=会議録除<))	46
#9	#1 OR #2 OR #3	5,855
#10	#4 OR #5 OR #6 OR #7 OR #8	12394
#11	#9 AND #10	290
#12	((("全身性炎症反応症候群"/TH) and (PT=会議録除<)) or (((敗血症/TH or Sepsis/AL)) and (PT=会議録除<)) or (Shock,/AL and Septic/AL)) and (((Dobutamine/TH or dobutamine/AL)) and (PT=会議録除<)) or (((Epinephrine/TH or epinephrine/AL)) and (PT=会議録除<)) or (((("Phosphoric Diester Hydrolases"/TH or phosphodiesterase/AL) and inhibitors/AL) and (PT=会議録除<)) or (((Aminopyridines/TH or aminopyridines/AL)) and (PT=会議録除<)) or (((Simendan/TH or simendan/AL)) and (PT=会議録除<)))	291

PRISMA フロー図



Gordon 2016



Random sequence generation (selection bias)



Allocation concealment (selection bias)



Blinding of participants and personnel (performance bias)



Blinding of outcome assessment (detection bias)



Incomplete outcome data (attrition bias)




Selective reporting (reporting bias)




Other bias

Forest/Funnel Plots

アウトカム① Short-term mortality (28 or 30days)



アウトカム② SOFA Score



アウトカム③ Arrhythmia

